V.TLT | January 27, 2025 TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses is proud to announce that its interim clinical data has been selected for presentation at the American Urological Association (“AUA“) Annual Meeting. The Program Committee of the AUA has accepted the Theralase®’s abstract titled: “Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ” for presentation in a Podium Session at the 2025 Annual Meeting of the American Urological Association to be held in Las Vegas, Nevada, April 26th to 29th. The clinical data from Theralase®’s international, multicenter Phase II (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) study will … Read More

V.TLT | December 9, 2024 Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®’s bladder cancer treatment TORONTO, ON / December 9, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched three new US-based Clinical Study Sites (“CSSs“) for its bladder cancer registrational clinical study; specifically: Associated Medical Professionals of NY (Syracuse, New York), Urology of Indiana (Greenwood, Indiana) and Central Ohio Urology Group (Gahanna, Ohio). The Principal Investigators (“PIs“) for the Theralase® clinical study at the new CSSs are as follows: Associated Medical Professionals of NY – Ilija Aleksic, MD Dr. … Read More

V.TLT | December 5, 2024 St. Joseph’s Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®’s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / December 5, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched a new Clinical Study Site (“CSS“) for its bladder cancer clinical study; specifically, St. Joseph’s Healthcare Hamilton (Hamilton, Ontario, Canada). Theralase®’s lead drug, RuvidarTM (TLD-1433), activated by the TLC-3200 Medical Laser System (“TLC-3200“) is currently under clinical investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) with or without resected … Read More

TORONTO, ON / November 27, 2024 / Theralase® Technologies Inc. (“ Theralase® ” or the “ Company “) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the Company’s unaudited condensed consolidated interim financial statements for the nine-month period ended September 30, 2024. (“ Financial Statements “). Theralase® will be hosting a conference call on Wednesday December 4 th at 11:00 am ET , which will include a presentation of the financial and operational results for the nine-month period ended September 30, 2024. Questions are welcome. To ensure Theralase® has time to review and properly address them during the call, please send them in advance to mperraton@theralase.com . Zoom Meeting Link: https://us02web.zoom.us/j/84816819001 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom. An archived version will be available on … Read More

TORONTO, ON / November 15, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering (“Offering“) of units (“Units“). On closing, the Corporation issued an aggregate of 2,221,334 Units at a price of $CAN 0.30 per Unit for aggregate gross proceeds of approximately $CAN 666,400. Each Unit consists of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.45 per share for a period of 5 years following the date of issuance. The Company plans to use the proceeds … Read More

TORONTO, ON / November 12, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 1,000,000 share purchase warrants (“Warrants“) from November 17, 2024 to November 17, 2027. The Warrants were issued on November 17, 2022, pursuant to a private placement involving the issuance of 1,000,000 units of the Company. The Warrants are exercisable at $0.35 per share. All other terms and conditions of the Warrants will remain unchanged. The warrant expiry date extension is subject to final acceptance by the TSX Venture Exchange. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, … Read More

TORONTO, ON / October 7, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it is providing an update on its bladder cancer clinical study. Theralase®’s lead drug, RuvidarTM, activated by the TLC-3200 Medical Laser System (“TLC-3200“) is currently under investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) with or without resected Ta / T1 papillary disease (“Study II“). In the United States, an estimated 83,190 patients will be diagnosed with bladder cancer.1 Bladder cancer was the fourth leading cancer in men in 2023, representing 6% of estimated new cancers and 4% of cancer related deaths. … Read More

TORONTO, ON / September 24, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a Non-Brokered Private Placement (“NBPP“) offering (“Offering“) of units (“Units“). On closing, the Corporation issued an aggregate of 2,720,000 Units at a price of $CAN 0.20 per Unit for aggregate gross proceeds of $CAN 544,000. Each Unit consists of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.30 per share for a period of 5 years following the date of issuance. The Company plans to use the proceeds … Read More

TORONTO, ON / September 19, 2024 / Theralase® Technologies Inc. (“Theralase” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 10,000,000 share purchase warrants (“Warrants“) from September 22, 2024 to September 22, 2027. The Warrants were issued on September 22, 2022, pursuant to a private placement involving the issuance of 10,000,000 units of the Company. The Warrants are exercisable at $0.35 per share. All other terms and conditions of the Warrants will remain unchanged. The warrant expiry date extension is subject to final acceptance by the TSX Venture Exchange. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, … Read More

Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery TORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it’s lead drug formulation, Ruvidar TM , has been demonstrated preclinically to be more effective in the destruction of the Herpes Simplex Virus 1 (“HSV-1“) than the currently approved standard of care drug, Acyclovir. Acyclovir is an antiviral drug used to slow the growth and spread of the HSV-1 virus in the body. Acyclovir will not cure herpes, but it can lessen the symptoms of the infection. It is used to treat infections caused by herpes viruses, such … Read More